Novo A/S

Nuevolution A/S, a privately held drug discovery company today announced that it has generated what it believes to be the world's largest drug-like library comprising 100 million diverse compounds synthesised in a single test tube. Nuevolution is a unique drug discovery company poised to revolutionize drug discovery and development by utilizing its proprietary Chemetics technology to rapidly generate tens to hundreds of potent, structurally diverse, small molecule clinical candidates to virtually any target in a matter of weeks. Nuevolution A/S currently employs 31 world-class scientists and business professionals, including 18 PhD qualified individuals. The company was founded in May 2001 and is currently headquartered in Copenhagen, Denmark. To date, Nuevolution has raised $24m in venture capital based on the ongoing development of its proprietary Chemetics technology. Nuevolution's investors include Novo A/S, Nordic Biotech K/S, Vækstfonden, SEB Företagsinvest and Scandinavian Life Science Venture. In the most recent investment, closed in October 2003, Nuevolution attracted Series B financing totalling $15m

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics